Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Burning Rock Biotech (BNR) EBT Margin (2019 - 2025)

Burning Rock Biotech has reported EBT Margin over the past 7 years, most recently at 11.48% for Q4 2025.

  • For Q4 2025, EBT Margin rose 4881.0% year-over-year to 11.48%; the TTM value through Dec 2025 reached 9.98%, up 5579.0%, while the annual FY2025 figure was 9.97%, 5609.0% up from the prior year.
  • EBT Margin for Q4 2025 was 11.48% at Burning Rock Biotech, up from 12.58% in the prior quarter.
  • Over five years, EBT Margin peaked at 6.37% in Q2 2025 and troughed at 200.29% in Q2 2022.
  • A 5-year average of 105.6% and a median of 131.39% in 2023 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: tumbled -9232bps in 2021 and later skyrocketed 11087bps in 2023.
  • Year by year, EBT Margin stood at 171.22% in 2021, then rose by 12bps to 150.68% in 2022, then grew by 12bps to 133.09% in 2023, then skyrocketed by 55bps to 60.29% in 2024, then skyrocketed by 81bps to 11.48% in 2025.
  • Business Quant data shows EBT Margin for BNR at 11.48% in Q4 2025, 12.58% in Q3 2025, and 6.37% in Q2 2025.